TY - JOUR
T1 - (2S,3R)β-methyl-2′,6′-dimethyltyrosine-L- tetrahydroisoquinoline-3-carboxylic acid [(2S,3R)TMT-L-Tic-OH] is a potent, selective δ opioid receptor antagonist in mouse brain
AU - Hosohata, Keiko
AU - Varga, Eva V.
AU - Alfaro-Lopez, Josue
AU - Tang, Xuejun
AU - Vanderah, Todd W.
AU - Porreca, Frank
AU - Hruby, Victor J.
AU - Roeske, William R.
AU - Yamamura, Henry I.
PY - 2003/2/1
Y1 - 2003/2/1
N2 - The constrained opioid peptide (2S,3R)β-methyl-2′,6′-dimethyltyrosine-L- tetrahydroisoquinoline-3-carboxylic acid [(2S,3R)TMT-L-Tic-OH] exhibits high affinity and selectivity for the δ-opioid receptors (Liao et al., 1997). In the present study, we examined the pharmacological properties of (2S,3R)TMT-L-Tic-OH in mouse brain. A 5′-O-(3-[35S]thiotriphosphate) ([35S]GTPγS) binding assay was used to determine the effect of (2S,3R)TMT-L-Tic-OH on G protein activity in vitro, in mouse brain membranes. δ-(SNC80; (+)-4-[(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl) -3-methoxy-benzyl]-N,N-diethyl-benzamide) or μ- (DAMGO; [D-Ala2, Me-Phe4, Gly(ol)5]enkephalin) selective opioid full agonists stimulated [35S]GTPγS binding in mouse brain membranes 150 ± 4.5% and 152 ± 5.7% over the basal level, respectively. (2S,3R)TMT-L-Tic-OH did not influence basal [35S]GTP±S binding in mouse brain membranes but dose dependently shifted the dose-response curve of SNC80 to the right, with a Ke value of 3.6 ± 0.7 nM. In contrast, (2S,3R)TMT-L-Tic-OH had no effect on the dose-response curve of the μ-selective opioid agonist, DAMGO. Warm water (55°C) tail-flick and radiant heat paw-withdrawal tests were used to determine the in vivo nociceptive properties of (2S,3R)TMT-L-Tic-OH in the mouse. Intracerebroventricular injection of (2S,3R)TMT-L-Tic-OH had no significant effect on withdrawal latencies in either nociceptive tests. (2S,3R)TMT-L-Tic-OH (30 nmol/mouse) attenuated deltorphin II- but not DAMGOmediated antinociception (40 ± 13 and 100% of maximal possible effect, respectively) when administered intracerebroventricularly 10 min before the agonist. Taken together these results suggest that (2S,3R)TMT-L-Tic-OH is a potent highly selective neutral δ-opioid antagonist in mouse brain.
AB - The constrained opioid peptide (2S,3R)β-methyl-2′,6′-dimethyltyrosine-L- tetrahydroisoquinoline-3-carboxylic acid [(2S,3R)TMT-L-Tic-OH] exhibits high affinity and selectivity for the δ-opioid receptors (Liao et al., 1997). In the present study, we examined the pharmacological properties of (2S,3R)TMT-L-Tic-OH in mouse brain. A 5′-O-(3-[35S]thiotriphosphate) ([35S]GTPγS) binding assay was used to determine the effect of (2S,3R)TMT-L-Tic-OH on G protein activity in vitro, in mouse brain membranes. δ-(SNC80; (+)-4-[(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl) -3-methoxy-benzyl]-N,N-diethyl-benzamide) or μ- (DAMGO; [D-Ala2, Me-Phe4, Gly(ol)5]enkephalin) selective opioid full agonists stimulated [35S]GTPγS binding in mouse brain membranes 150 ± 4.5% and 152 ± 5.7% over the basal level, respectively. (2S,3R)TMT-L-Tic-OH did not influence basal [35S]GTP±S binding in mouse brain membranes but dose dependently shifted the dose-response curve of SNC80 to the right, with a Ke value of 3.6 ± 0.7 nM. In contrast, (2S,3R)TMT-L-Tic-OH had no effect on the dose-response curve of the μ-selective opioid agonist, DAMGO. Warm water (55°C) tail-flick and radiant heat paw-withdrawal tests were used to determine the in vivo nociceptive properties of (2S,3R)TMT-L-Tic-OH in the mouse. Intracerebroventricular injection of (2S,3R)TMT-L-Tic-OH had no significant effect on withdrawal latencies in either nociceptive tests. (2S,3R)TMT-L-Tic-OH (30 nmol/mouse) attenuated deltorphin II- but not DAMGOmediated antinociception (40 ± 13 and 100% of maximal possible effect, respectively) when administered intracerebroventricularly 10 min before the agonist. Taken together these results suggest that (2S,3R)TMT-L-Tic-OH is a potent highly selective neutral δ-opioid antagonist in mouse brain.
UR - http://www.scopus.com/inward/record.url?scp=0037308137&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037308137&partnerID=8YFLogxK
U2 - 10.1124/jpet.102.042929
DO - 10.1124/jpet.102.042929
M3 - Article
C2 - 12538822
AN - SCOPUS:0037308137
SN - 0022-3565
VL - 304
SP - 683
EP - 688
JO - Journal of Pharmacology and Experimental Therapeutics
JF - Journal of Pharmacology and Experimental Therapeutics
IS - 2
ER -